Stockreport

Immune Pharmaceuticals' Bertilimumab receives Fast Track designation for the treatment of bullous pemphigoid [Seeking Alpha]

IMMUNE PHARMACEUTICALS INC NE  (IMNP) 
US:NASDAQ Investor Relations: immunepharma.com/investor-relations
PDF Immune Pharmaceuticals' Bertilimumab receives Fast Track designation for the treatment of bullous pemphigoid [Read more]